Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

85.00CHF
9:18am GMT
Change (% chg)

CHF0.34 (+0.40%)
Prev Close
CHF84.66
Open
CHF84.98
Day's High
CHF85.66
Day's Low
CHF84.68
Volume
1,051,380
Avg. Vol
4,629,003
52-wk High
CHF92.80
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  NOVN.S Industry Sector
P/E (TTM): 31.37 31.13 34.40
EPS (TTM): 2.68 -- --
ROI: 6.14 15.55 14.96
ROE: 9.19 16.92 16.53

BRIEF-Novartis - Sandoz Sandoz Enters Into Commercialization Agreement With Gan & Lee

* SANDOZ ENTERS INTO COMMERCIALIZATION AND SUPPLY AGREEMENT FOR INSULIN BIOSIMILARS, ANTICIPATING GROWING DEMAND AS DIABETES BURDEN RISES

6:53am GMT

BRIEF-Anji Pharmaceuticals Says Licensed Pradigastat From Novartis

* ANJI PHARMACEUTICALS - ANNOUNCED IT HAS LICENSED PRADIGASTAT, AN INHIBITOR OF ACYL COA: DIACYLGLYCEROL ACYL TRANSFERASE (DGAT1), FROM NOVARTIS Source text for Eikon: Further company coverage:

1:27am GMT

BRIEF-Endocyte Inc Says CFIUS Declaration Review Period With Respect To Novartis Deal Expired On Dec. 14

* ENDOCYTE INC - CFIUS DECLARATION REVIEW PERIOD WITH RESPECT TO NOVARTIS DEAL EXPIRED ON DECEMBER 14, 2018

17 Dec 2018

BRIEF-Novartis Receives European Approval For Self-Administration Of Xolair

* NOVARTIS RECEIVES EUROPEAN COMMISSION APPROVAL FOR SELF-ADMINISTRATION OF XOLAIR® ACROSS ALL INDICATIONS

13 Dec 2018

J&J says its psoriasis drug superior to Novartis treatment in study

Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

12 Dec 2018

UPDATE 2-J&J says its psoriasis drug superior to Novartis treatment in study

Dec 12 Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

12 Dec 2018

BRIEF-Novartis Says Data From Eclipse Trial "Really Doesn't Change" Plans For Cosentyx

* WE BELIEVE DATA FROM ECLIPSE TRIAL, WHICH TESTED NOVARTIS' COSENTYX AGAINST JNJ'S TREMFYA , WILL HAVE LIMITED CLINICAL RELEVANCE - NOVARTIS EXECUTIVE SAYS ON CONF. CALL

12 Dec 2018

J&J says its psoriasis drug superior to Novartis' in study

Dec 12 Johnson & Johnson said on Wednesday its drug Tremfya was more effective than a rival medicine from Novartis AG, and met the main goal of a late-stage study in adults with moderate to severe plaque psoriasis.

12 Dec 2018

Swiss stocks - Factors to watch on Dec. 11

ZURICH/BERLIN, Dec 11 The Swiss blue-chip SMI was seen opening 1.0 percent higher at 8,634 points on Tuesday, according to premarket indications by bank Julius Baer .

11 Dec 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

07 Dec 2018

Earnings vs. Estimates